PA Fasching

Activity Levels of Tamoxifen Metabolites at the Estrogen Receptor and the Impact of Genetic Polymorphisms of Phase I and II Enzymes on Their Concentration Levels in Plasma

T E Mürdter, Werner Schroth, L. Bacchus-Gerybadze et al. · Clinical Pharmacology & Therapeutics · 2011 · 268 citations

Medicine, Pharmacokinetics, Pharmacology +17

Factors correlating with reexcision after breast-conserving therapy

Mayada R. Bani, Michael P. Lux, Katharina Heusinger et al. · European Journal of Surgical Oncology · 2008 · 101 citations

Medicine, Oncology, Surgery +6

Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant

Patrick Neven, PA Fasching, Stephen Chia et al. · Breast Cancer Research · 2023 · 72 citations · Full text

Medicine, Oncology, Pharmacology +16

Abstract S2-04: Early survival analysis of the randomized phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer (GeparSixto)

Gϋnter von Minckwitz, Sibylle Loibl, C. Salat et al. · Cancer Research · 2016 · 62 citations

Medicine, Oncology, Pharmacology +17

Awareness of breast cancer incidence and risk factors among healthy women

Uwe Pöhls, Stefan P. Renner, PA Fasching et al. · European Journal of Cancer Prevention · 2004 · 59 citations

Medicine, Oncology, Preventive Medicine +13